May 8 |
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
|
May 8 |
Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
May 7 |
Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
|
May 7 |
Madrigal sees ‘tremendous interest’ in new NASH drug Rezdiffra
|
May 7 |
Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch
|
May 7 |
Madrigal Pharmaceuticals GAAP EPS of -$7.38 misses by $1.18
|
May 7 |
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
|
May 6 |
Madrigal Pharmaceuticals Q1 2024 Earnings Preview
|
Apr 30 |
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
|
Apr 24 |
Madrigal Statement on the Passing of Dr. Stephen Harrison
|